Douglas W.P. Hay - Concepedia

Author

Douglas W.P. Hay

New Frontier

Also Known As

D Hay, D Hay', D W Hay, D W P Hay, D. W. HAY, D. W. P. HAY, D. W. P. Hay, D.W.P Hay, D.W.P. HAY, D.W.P. Hay

171

Publications

8.2K

Citations

H-Index

Concepts

All Affiliations

New Frontier National Institute for Occupational Safety and Health University of Strathclyde The University of Western Australia GlaxoSmithKline (United States)

About

Douglas W.P. Hay is an author at New Frontier specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	43	2.9K
2	Natural Sciences	5	5	247
3	Health Sciences	2	2	44
4	Engineering	1	1	15
5	Public Health	1	1	25

Douglas W.P. Hay

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 Robert S. Ames, Henry M. Sarau, Johathan K. Chambers, Nature Molecular PharmacologyUrologyG Protein-coupled ReceptorMedicineOrphan Receptor Gpr14	1999	788
Identification, Molecular Cloning, Expression, and Characterization of a Cysteinyl Leukotriene Receptor Henry M. Sarau, Robert S. Ames, Jon Chambers, Molecular Pharmacology	1999	341
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung David C. Underwood, Ruth R. Osborn, Steven Bochnowicz, American Journal of Physiology-Lung Cellular and Molecular Physiology AsthmaAntifibrotic TherapyInflammatory Lung DiseaseAdvanced Lung DiseaseLung Inflammation	2000	297
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery Rajendra H. Mehta, Jeffrey D. Leimberger, Sean van Diepen, New England Journal of Medicine	2017	294
Effects of LTD <sub>4</sub> on Human Airway Smooth Muscle Cell Proliferation, Matrix Expression, and Contraction <i>In Vitro</i> : Differential Sensitivity to Cysteinyl Leukotriene Receptor Antagonists Reynold A. Panettieri, Elaine M. L. Tan, Vincenzo Ciocca, American Journal of Respiratory Cell and Molecular Biology	1998	272
SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence David C. Underwood, Ruth R. Osborn, Charles J. Kotzer, Journal of Pharmacology and Experimental Therapeutics	2000	244
Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. Theodore J. Torphy, Bradley J. Undem, L B Cieslinski, Journal of Pharmacology and Experimental Therapeutics	1993	165
A Potent and Selective Nonpeptide Antagonist of CXCR2 Inhibits Acute and Chronic Models of Arthritis in the Rabbit Patricia L. Podolin, Brian Bolognese, James J. Foley, The Journal of Immunology	2002	161
Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. Douglas W.P. Hay, Roseanna M. Muccitelli, Stephanie S. Tucker, PubMed Lung InflammationPharmacotherapyExperimental PharmacologyCellular PhysiologyHuman Airways	1987	147
Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. David C. Underwood, Ruth R. Osborn, S J Newsholme, American Journal of Respiratory and Critical Care Medicine InflammationAsthmaInflammatory Lung DiseaseAllergyLung Inflammation	1996	141

Page 1